OKUR

Onkure Therapeutics Inc

Add to Watchlist

Advanced Chart

1.920

-0.080(-4.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

2.050

Open

1.990

VWAP

1.92

Vol

185.91K

Mkt Cap

25.94M

Low

1.830

Amount

357.08K

EV/EBITDA(TTM)

Total Shares

13.51M

-70.72M

EV/OCF(TTM)

P/S(TTM)

OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KαH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3Kα and has multiple programs designed to enable targeting of this key oncogene.

5 Analyst Rating

1553.65% Upside

Wall Street analysts forecast OKUR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OKUR is 31.75 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

1553.65% Upside

Current: 1.920

Low

30.00

Averages

31.75

High

34.00

1553.65% Upside

Current: 1.920

Low

30.00

Averages

31.75

High

34.00

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$40 → $34

2025-03-18

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$40 → $34

2025-03-18

Maintains

Strong Buy

Reason

Oppenheimer

Matt Biegler

Buy

Maintains

$35 → $30

2025-03-11

Reason

Oppenheimer

Matt Biegler

Price Target

$35 → $30

2025-03-11

Maintains

Buy

Reason

Oppenheimer lowered the firm's price target on OnKure Therapeutics to $30 from $35 but keeps an Outperform rating on the shares after its Q4 results. The firm's post-earnings discussion with the company revealed that an important update from PIKture-01 is slated for the second half of 2025 and should provide enough data to make a determination on OKI-219's competitive profile relative to RLY-2608 and STX-478, the analyst tells investors in a research note. While OKI-219 is ultra-selective for common H1047R mutant, the company is also being more vocal about its pan-mutant inhibitor pipeline, the firm adds.

Jones Trading

Soumit Roy

Strong Buy

Initiates

$32

2025-01-28

Reason

Jones Trading

Soumit Roy

Price Target

$32

2025-01-28

Initiates

Strong Buy

Reason

JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology company is developing targeted PI3Kalpha inhibitors for the treatment of breast cancer and other solid tumors with mutations in the PIK3CA gene, notes the analyst, who points out that this space has come under spotlight recently following the acquisition of Scorpion Therapeutics by Eli Lilly (LLY) in January for up to $2.5B. OnKure's lead asset, OKI-219, is a small molecule point-mutation specific inhibitor that targets PI3Kalpha harboring a H1047R mutation, notes the analyst, who adds that OKI-219 has "the potential to be the first approved mutation-specific PI3Kalpha inhibitor."

Leerink Partners

Andrew Berens

Buy

Initiates

$33

2024-12-05

Reason

Leerink Partners

Andrew Berens

Price Target

$33

2024-12-05

Initiates

Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Reiterates

$40

2024-11-08

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$40

2024-11-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Robert Burns

Strong Buy

Initiates

$40

2024-10-17

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$40

2024-10-17

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Onkure Therapeutics Inc (OKUR.O) is -0.44, compared to its 5-year average forward P/E of -2.42. For a more detailed relative valuation and DCF analysis to assess Onkure Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.42

Current PE

-0.44

Overvalued PE

-0.22

Undervalued PE

-4.62

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

45.21

Current PS

161.20

Overvalued PS

112.16

Undervalued PS

-21.75